Skip to main content
HR 4209 112th Congress House Health Employee benefits and pensions Health care costs and insurance Prescription drugs

Patients' Access to Treatments Act of 2012

Introduced: September 12, 2012 See on congress.gov
This bill died when the 112th Congress ended
It never became law before the 112th Congress (2011–2012) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 19, 2012
Introduced in House
Mar 19, 2012
Referred to the House Committee on Energy and Commerce.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Patients' Access to Treatments Act of 2012 - Amends the Public Health Service Act to prohibit a health plan offering group or individual health insurance that provides coverage for prescription drugs and uses a formulary or other tiered cost-sharing structure from imposing co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier that exceed the dollar amount of such requirements applicable to prescription drugs in a non-preferred brand drug tier.

Provides that if a formulary used by such a health plan contains more than one non-preferred brand drug tier, such prohibition shall be applied with respect to the non-preferred brand drug tier for which beneficiary cost-sharing is lowest.

Defines: (1) "non-preferred brand drug tier" as a category of drugs within a tier in such formulary for which beneficiary cost-sharing is greater than tiers for generic drugs or preferred brand drugs in the plan's formulary, that are prescription drugs, and that are not included within a specialty drug tier; and (2) "specialty drug tier" as a category of drugs within a tier in such formulary for which beneficiary cost-sharing is greater than tiers for generic drugs, preferred brand drugs, or non-preferred drugs in the plan's formulary and that are prescription drugs.

What's happening now March 19, 2012

Referred to the House Committee on Energy and Commerce.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 4209: Patients' Access to Treatments Act of 2012. 112th Congress. Open America. https://openamerica.io/bill/112-HR-4209/
MLA
"H.R. 4209: Patients' Access to Treatments Act of 2012." 112th Congress, 2026, Open America, https://openamerica.io/bill/112-HR-4209/.
Bluebook (legal)
H.R. 4209, 112th Cong. (2026), https://openamerica.io/bill/112-HR-4209/.
Markdown link
[H.R. 4209: Patients' Access to Treatments Act of 2012](https://openamerica.io/bill/112-HR-4209/)
Report a problem